Beca Francisco, Oh Hannah, Collins Laura C, Tamimi Rulla M, Schnitt Stuart J
Department of Pathology, Stanford University Medical School, Stanford, CA, USA.
Interdisciplinary Program in Precision Public Health, College of Health Sciences, Korea University, Seoul, South Korea.
NPJ Breast Cancer. 2021 Mar 5;7(1):23. doi: 10.1038/s41523-021-00225-9.
Data on the risk of breast cancer following a benign breast disease (BBD) diagnosis were derived predominantly from populations of women biopsied before the widespread use of mammographic screening and in whom these lesions were mostly incidental findings. Whether or not similar risk associations are seen when these lesions are detected in mammographically screened populations is unknown. To address this, we examined the variation in BBD and breast cancer risk associations by the calendar time of BBD diagnosis (pre- vs. post-mammography era [before vs. 1985 and after]) in a nested case-control study within the Nurses' Health Study (NHS) and NHSII BBD subcohort (488 cases; 1908 controls). We performed logistic regression analysis, adjusting for matching factors and potential confounders, to estimate odds ratio (ORs) and 95% confidence interval (CI) for the association between BBD subtype (non-proliferative, proliferative without atypia, proliferative with atypical hyperplasia (AH)) and subsequent breast cancer risk. When compared with non-proliferative lesions, both proliferative lesions without atypia (PWA) and AHs were associated with similar levels of risk in the pre-mammographic (pre) and post-mammographic (post) time periods (PWA: OR [95% CI] = 1.73 [1.27, 2.36] pre vs. 1.12 [0.73, 1.74] post; AH: 4.41 [2.90, 6.70] pre vs. 3.69 [2.21, 6.15] post). The interaction by mammography era was not statistically significant (p-interaction = 0.47). These results suggest that the risk associations reported for BBD subtypes in the pre-mammography era remain valid for BBD detected after the widespread implementation of mammographic screening.
良性乳腺疾病(BBD)诊断后患乳腺癌风险的数据主要来源于在乳腺钼靶筛查广泛应用之前接受活检的女性群体,且这些病变大多为偶然发现。在接受乳腺钼靶筛查的人群中检测到这些病变时是否会出现类似的风险关联尚不清楚。为解决这一问题,我们在护士健康研究(NHS)和NHSII的BBD亚队列(488例病例;1908例对照)的巢式病例对照研究中,按BBD诊断的日历时间(乳腺钼靶检查前与后时代[1985年之前与之后])检查了BBD与乳腺癌风险关联的差异。我们进行了逻辑回归分析,对匹配因素和潜在混杂因素进行了调整,以估计BBD亚型(非增殖性、无非典型性增生的增殖性、有非典型增生(AH)的增殖性)与随后乳腺癌风险之间关联的比值比(OR)和95%置信区间(CI)。与非增殖性病变相比,在乳腺钼靶检查前(pre)和乳腺钼靶检查后(post)时期,无非典型性增生的增殖性病变(PWA)和AHs的风险水平相似(PWA:OR[95%CI]=1.73[1.27,2.36]pre对比1.12[0.73,1.74]post;AH:4.41[2.90,6.70]pre对比3.69[2.21,6.15]post)。乳腺钼靶检查时代的交互作用无统计学意义(p交互作用=0.47)。这些结果表明,在乳腺钼靶检查前时代报告的BBD亚型风险关联对于在乳腺钼靶筛查广泛实施后检测到的BBD仍然有效。